Ibikunle Adebayo Aremu, Adeyemo Wasiu Lanre, Ladeinde Akinola Ladipo
Department of Dental and Maxillofacial Surgery, Usmanu Danfodiyo University Teaching Hospital, Sokoto, Nigeria.
Department of Oral and Maxillofacial Surgery, Faculty of Dental Sciences, College of Medicine University of Lagos, Lagos, Nigeria.
Oral Maxillofac Surg. 2016 Dec;20(4):343-352. doi: 10.1007/s10006-016-0571-4. Epub 2016 Jul 22.
The aim of this study was to evaluate the changes in oral health-related Quality of Life (QoL) following third molar surgery with either oral administration or submucosal injection of prednisolone.
Subjects were randomly distributed into three groups of 62 subjects each: Group A consisted of subjects who received 40 mg oral prednisolone; group B received 40 mg submucosal injection of prednisolone, while group C did not receive prednisolone. Preoperative and postoperative quality of life evaluations of all subjects were done using the 14-item Oral Health Impact Profile (OHIP-14) questionnaire. Postoperatively, quality of life evaluation was done on postoperative days 1, 3, and 7. Subjects were categorized as either affected (OHIP score ≤28) or not affected (OHIP score >28). Mean OHIP scores between preoperative and postoperative periods, as well as between the three groups, were compared.
A significant increase in the mean total and subscale scores was found in all the groups postoperatively. This was most marked on the first postoperative day, and it gradually improved throughout the immediate postoperative period. Subjects who received prednisolone experienced a statistically significant better quality of life than those who did not. Subjects who received submucosal injection of prednisolone showed statistically significant less deterioration in QoL than those who received oral prednisolone (P = 0.001).
Administration of prednisolone was significantly associated with less deterioration in quality of life and earlier recovery when compared with subjects who did not receive prednisolone. Submucosal injection of prednisolone 40 mg (which offers a simple, safe, painless, and cost-effective therapeutic option) is an effective therapeutic strategy for improving the quality of life after surgical removal of impacted lower third molars.
本研究旨在评估口服或黏膜下注射泼尼松龙的第三磨牙手术后口腔健康相关生活质量（QoL）的变化。
将受试者随机分为三组，每组62名受试者：A组由接受40mg口服泼尼松龙的受试者组成；B组接受40mg泼尼松龙黏膜下注射，而C组未接受泼尼松龙。所有受试者术前和术后的生活质量评估均使用14项口腔健康影响量表（OHIP-14）问卷进行。术后，在术后第1、3和7天进行生活质量评估。受试者被分类为受影响（OHIP评分≤28）或未受影响（OHIP评分>28）。比较术前和术后期间以及三组之间的平均OHIP评分。
所有组术后平均总分及各子量表评分均显著增加。这在术后第一天最为明显，并在术后即刻期间逐渐改善。接受泼尼松龙的受试者的生活质量在统计学上显著优于未接受的受试者。接受泼尼松龙黏膜下注射的受试者的生活质量恶化程度在统计学上显著低于接受口服泼尼松龙的受试者（P = 0.001）。
与未接受泼尼松龙的受试者相比，泼尼松龙的给药与生活质量恶化程度较低和恢复较早显著相关。40mg泼尼松龙黏膜下注射（提供了一种简单、安全、无痛且经济有效的治疗选择）是改善拔除下颌阻生第三磨牙术后生活质量的有效治疗策略。
